201. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose
- Author
-
Luciana Spataru, Laurence Lavayssière, Nassim Kamar, Lionel Rostaing, Dominique Durand, Laure Esposito, Isabelle Gennero, Olivier Cointault, Joelle Guitard, Peggy Gandia, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biochimie [Purpan], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Pharmacocinétique et de Toxicologie clinique [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biochimie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire Pharmacocinétique et de Toxicologie [CHU Toulouse], and Simon, Marie Francoise
- Subjects
Male ,Cinacalcet ,030232 urology & nephrology ,Parathyroid hormone ,030204 cardiovascular system & hematology ,MESH: Cyclosporine ,MESH: Kidney Transplantation ,MESH: Dose-Response Relationship, Drug ,0302 clinical medicine ,Longitudinal Studies ,Prospective Studies ,MESH: Longitudinal Studies ,MESH: Phosphorus ,Kidney transplantation ,MESH: Aged ,MESH: Middle Aged ,Phosphorus ,MESH: Naphthalenes ,Middle Aged ,MESH: Hyperparathyroidism, Secondary ,3. Good health ,MESH: Parathyroid Hormone ,Parathyroid Hormone ,Nephrology ,MESH: Kidney Failure, Chronic ,MESH: Calcium ,Cyclosporine ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Hypercalcaemia ,Urology ,Renal function ,Naphthalenes ,Tacrolimus ,MESH: Hypercalcemia ,03 medical and health sciences ,Internal medicine ,medicine ,MESH: Tacrolimus ,Humans ,Aged ,Calcium metabolism ,Transplantation ,Hyperparathyroidism ,MESH: Humans ,Dose-Response Relationship, Drug ,business.industry ,MESH: Adult ,medicine.disease ,Kidney Transplantation ,MESH: Male ,MESH: Prospective Studies ,Endocrinology ,Hypercalcemia ,Kidney Failure, Chronic ,Calcium ,Hyperparathyroidism, Secondary ,business ,MESH: Female ,Kidney disease - Abstract
International audience; BACKGROUND: In the setting of kidney transplantation, cinacalcet has been given, mainly, once daily, but also twice daily. The aims of this prospective study were to assess the acute pharmacodynamic effect of cinacalcet administrated once or twice daily to kidney transplant patients with normal renal function and persisting hypercalcaemia due to hyperparathyroidism and to evaluate 1-year efficacy and tolerance of cinacalcet given at a dose of 30 mg b.i.d. METHODS: Eleven patients, who received a transplant 6 (6-59) months previously, were included in the study. A first kinetic was done after administration of 60 mg of cinacalcet at 8 a.m. After a washout period of 1 week, the second kinetic was performed with cinacalcet given at 30 mg b.i.d within a 12-h period. RESULTS: During both kinetics, serum calcium (sCa), ionized calcium (sCa(2+)), albumin-corrected Ca and parathyroid hormone (PTH) levels decreased significantly. At 24 h after the second kinetic, sCa(2+) was significantly lower. After 1 year of cinacalcet treatment, given at the dose of 30 mg b.i.d., there was a significant decrease in sCa, sCa(2+), PTH levels and calcium x phosphorus (Ph) product. In contrast, Ph levels increased significantly. There was no significant change in renal function. CONCLUSION: Once- or twice-daily acute administration of cinacalcet to kidney-transplant patients has similar efficacy. One-year administration of cinacalcet, given as two daily doses, is safe and efficient.
- Published
- 2008